The UK is witnessing a growing surge in interest surrounding entheogenic substances. Beyond the common use of psilocybin and LSD, investigators and enthusiasts are increasingly exploring less-charted territories, particularly the copyright compound and the relatively new cannabinoid, cannabigerol. The evolving community encompasses therapeutic rese